Merck & Co., Inc. (MSD; NYSE: MRK) announced that China’s National Medical Products Administration (NMPA) has approved an expanded indication for Winrevair (sotatercept for injection) — the treatment of adult patients with Pulmonary Arterial Hypertension (PAH, WHO Group 1) with WHO Functional Class (FC) II–IV, to improve exercise capacity and WHO functional class, and to reduce the risk of clinical worsening events, including PAH hospitalization, lung transplantation, and death.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Expanded indication (supplemental approval) |
| Product | Winrevair (sotatercept for injection) |
| Drug Class | Activin Signaling Inhibitor (ASI) — first in class |
| Expanded Indication | Adult PAH (WHO Group 1), WHO FC II–IV: improve exercise capacity and WHO functional class; reduce risk of clinical worsening events including PAH hospitalization, lung transplantation, and death |
| Pivotal Evidence | Phase III ZENITH and HYPERION clinical trials |
| Prior China Approval | January 2026 — adult PAH (WHO Group 1), WHO FC II–III, to improve exercise capacity and WHO functional class |
| Approval Date | 11 Sep 2026 (announced) |
| Detailed Trial Data | Not disclosed in announcement |
Drug Profile & Mechanism of Action
- Molecule: Sotatercept — an Activin Signaling Inhibitor (ASI) administered by injection, representing a new mechanistic class in PAH therapy.
- Target: The activin signaling axis implicated in the underlying pathophysiology of PAH, in contrast to conventional therapies that act primarily on vasodilatory pathways.
- Mechanism: By rebalancing pro‑proliferative and anti‑proliferative signaling, sotatercept improves vascular and right ventricular remodeling, addressing the disease at its root rather than only relieving symptoms.
- Clinical Benefit Profile: The expanded label covers hard prognostic endpoints — reduction of clinical worsening events including hospitalization, lung transplantation, and death — beyond functional improvement alone.
Disease & Evidence Context
- PAH Burden: Pulmonary arterial hypertension (WHO Group 1) is a progressive, life‑threatening vascular disorder of the pulmonary circulation leading to right heart failure; FC II–IV patients span moderate to severe disease with substantial unmet need in China.
- Indication Broadening: The January 2026 approval covered FC II–III; the new label extends treatment to FC IV — the most severe functional class — widening the eligible patient population.
- Pivotal Trials: The expansion is supported by data from the Phase III ZENITH and HYPERION trials; specific efficacy endpoints and numerical results were not disclosed in the announcement.
- Right Ventricular Remodeling: Addressing vascular and right ventricular remodeling positions sotatercept as a potentially disease‑modifying therapy, complementary to background vasodilator regimens.
Market Impact & Outlook
- China PAH Landscape: With a large diagnosed‑and‑undiagnosed patient population and improving specialty care infrastructure, China represents a strategic growth market for advanced PAH therapies; the expanded label significantly broadens Winrevair’s addressable patient base.
- Commercial Momentum: The supplemental approval, just eight months after Winrevair’s initial China launch in January 2026, strengthens Merck’s cardiopulmonary franchise positioning in one of the company’s key growth pillars.
- First‑in‑Class Advantage: As the only approved Activin Signaling Inhibitor, sotatercept faces no direct mechanistic competition in China’s PAH market, differentiating it from established prostacyclin, endothelin receptor antagonist and PDE5 inhibitor therapies.
- Hard‑Endpoint Value: Label language covering reduction of hospitalization, lung transplantation and death provides a compelling value proposition for payers, physicians and patients relative to symptom‑focused comparators.
- Access & Reimbursement: Pricing and National Reimbursement Drug List (NRDL) negotiation status were not disclosed; reimbursement access will be a key determinant of uptake.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Winrevair (sotatercept) in China, including commercialization of the expanded indication, market adoption and patient access. Actual results may differ materially due to risks including reimbursement and pricing negotiations, competitive developments, regulatory requirements, and real‑world safety and efficacy experience.-Fineline Info & Tech
